CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020
- COVID-19 prophylactic vaccine candidate: CVnCoV on track for advanced clinical testing
- Interim Phase 1 data showed generally good tolerability for CVnCoV and strong antibody responses in addition to first indication of T cell activation
- Stability confirmed for at least three months at standard refrigerator temperature and for up to 24 hours at room temperature
- Pivotal Phase 2b/3 to be initiated shortly with 12µg dose
- Agreement with European Commission to supply 225 million doses of CVnCoV and an option for an additional 180 million doses
- Building a strong European manufacturing network to supply up to 300 million doses by end of 2021 and up to 600 million doses by the end of 2022
- Phase 1 results for oncology lead candidate, CV8102, confirm tolerability and responses in additional cancer indication
- Financials: Cash position of €892 million as of September 30, 2020
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced business updates and financial results for the third quarter and first nine months of 2020.